Cortex Pharmaceuticals Inc.

The Irvine neuroscience company, which focuses on treatments for neurological and psychiatric disorders, reported a second quarter net loss of $372,000, or 2 cents a share, compared with a net loss of $423,000, or 3 cents a share, for the like period last year. Revenue, which was generated from research support, declined 16% to $836,000 for the three months ended Dec. 31.